Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.7 USD | -0.21% | +3.30% | +68.46% |
May. 01 | Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154 | CI |
Apr. 12 | Lipocine Says LPCN 2401 Shows Improved Body Composition in Mid-Stage Trial | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+68.46% | 25.14M | |
-1.65% | 103B | |
+6.75% | 101B | |
+6.52% | 23.07B | |
-12.60% | 22.23B | |
-4.69% | 18.05B | |
-39.98% | 17.18B | |
-10.17% | 16.94B | |
+6.12% | 14.07B | |
+35.47% | 12.35B |
- Stock Market
- Equities
- LPCN Stock
- News Lipocine Inc.
- Lipocine Enters Licensing Deal With Verity Pharmaceuticals for TLANDO in US, Canada